{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yu M"],"funding":["American Heart Association","NHLBI NIH HHS","American Foundation for Pharmaceutical Education","NINDS NIH HHS","National Institutes of Health","Pharmaceutical Research and Manufacturers of America Foundation","NIGMS NIH HHS"],"pagination":["5454-5462"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10916337"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(11)"],"pubmed_abstract":["Phosphatidylserine (PS) is an anionic phospholipid component in endogenous high-density lipoprotein (HDL). With the intrinsic anti-inflammatory effects of PS and the correlation between PS content and HDL functions, it was hypothesized that incorporating PS would enhance the therapeutic effects of HDL mimetic particles. To test this hypothesis, a series of synthetic high-density lipoproteins (sHDLs) were prepared with an apolipoprotein A-I (ApoA-1) mimetic peptide, 1-palmitoyl-2-oleoyl-<i>glycero</i>-3-phosphocholine (POPC), and 1-palmitoyl-2-oleoyl-<i>glycero</i>-3-phospho-l-serine (POPS). Incorporating PS was found to improve the particle stability of sHDLs. Moreover, increasing the PS content in sHDLs enhanced the anti-inflammatory effects on lipopolysaccharide-activated macrophages and endothelial cells. The incorporation of PS had no negative impact on cholesterol efflux capacity, <i>in vivo</i> cholesterol mobilization, and did not affect the pharmacokinetic profiles of sHDLs. Such results suggest the therapeutic potential of PS-containing sHDLs for inflammation resolution in atherosclerosis and other inflammatory diseases."],"journal":["Molecular pharmaceutics"],"pubmed_title":["Enhancement of Anti-inflammatory Effects of Synthetic High-Density Lipoproteins by Incorporation of Anionic Lipids."],"pmcid":["PMC10916337"],"funding_grant_id":["R01 GM113832","19PRE34400017","T32 HL125242","R21 NS111191","T32 GM007767"],"pubmed_authors":["Yu M","Schwendeman A","Dorsey KH","Halseth T"],"additional_accession":[]},"is_claimable":false,"name":"Enhancement of Anti-inflammatory Effects of Synthetic High-Density Lipoproteins by Incorporation of Anionic Lipids.","description":"Phosphatidylserine (PS) is an anionic phospholipid component in endogenous high-density lipoprotein (HDL). With the intrinsic anti-inflammatory effects of PS and the correlation between PS content and HDL functions, it was hypothesized that incorporating PS would enhance the therapeutic effects of HDL mimetic particles. To test this hypothesis, a series of synthetic high-density lipoproteins (sHDLs) were prepared with an apolipoprotein A-I (ApoA-1) mimetic peptide, 1-palmitoyl-2-oleoyl-<i>glycero</i>-3-phosphocholine (POPC), and 1-palmitoyl-2-oleoyl-<i>glycero</i>-3-phospho-l-serine (POPS). Incorporating PS was found to improve the particle stability of sHDLs. Moreover, increasing the PS content in sHDLs enhanced the anti-inflammatory effects on lipopolysaccharide-activated macrophages and endothelial cells. The incorporation of PS had no negative impact on cholesterol efflux capacity, <i>in vivo</i> cholesterol mobilization, and did not affect the pharmacokinetic profiles of sHDLs. Such results suggest the therapeutic potential of PS-containing sHDLs for inflammation resolution in atherosclerosis and other inflammatory diseases.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2025-04-04T03:06:17.92Z","creation":"2025-04-04T03:06:17.92Z"},"accession":"S-EPMC10916337","cross_references":{"pubmed":["37781907"],"doi":["10.1021/acs.molpharmaceut.3c00175"]}}